You searched for "surgical"

643 results found

EMS Successful PCNL with the Swiss LithoClast® Trilogy Max

EMS and the Hospital team of Prof. Thomas Knoll in Sindelfingen, Germany are delighted to have you for our 1-day program focused on advanced techniques performing a successful PCNL. The session comprises a combination of didactic presentations and live case observation on surgical techniques, tips & tricks, and medical management of stone patients.

IRCAD France: Robotic Pediatric Surgery and Urology Advanced Course

This 2-day course will cover a broad spectrum of surgical procedures in robotic pediatric surgery and urology, and will be divided into two parts with one morning dedicated to theoretical training, and the rest of the course entirely dedicated to hands-on training.

EMS Prostate Enucleation by TFL – Step by Step Guide

The EMS and Metro Specialist Hospital teams in Malaysia are thrilled to welcome you to our 1.5- day program that focuses on advanced techniques for BPH by TFL. During this session, you will have the opportunity to attend didactic presentations and observe live cases showcasing surgical techniques, helpful tips and tricks, and medical management strategies for stone patients.

EMS Benign prostatic hyperplasia (BPH)

The Masterclass comprises a combination of didactic presentations, as-live surgery presentations, and live case observation on surgical techniques, tips and tricks, and the medical management of Benign prostatic hyperplasia (BPH) patients.

EMS Benign prostatic hyperplasia (BPH) Masterclass

The Masterclass comprises a combination of didactic presentations, as-live surgery presentations, and live case observation on surgical techniques, tips and tricks, and the medical management of Benign prostatic hyperplasia (BPH) patients.

Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high-risk UTUC

High-risk upper tract urothelial carcinoma (UTUC) has been associated with poor survival outcomes. The authors evaluated the role of neoadjuvant chemotherapy in high-risk cases prior to radical nephroureterectomy (RNU) in terms of pathological stage of the final surgical specimen. A...

Cryotherapy in prostate cancer

This review of the literature aims to summarise what is known in regards to outcomes in patients undergoing cryotherapy in a number of settings: whole gland, salvage and targeted focal therapy. It highlights that more prostate cancers are being diagnosed...

Outcomes of sarcomatoid differentiation in urothelial carcinoma

Sarcomatoid differentiation is a rare variant of urothelial carcinoma (UC) seen in 0.6% of cases. Its response to neo-adjuvant chemotherapy (NAC) has not been well reported. The authors have done a retrospective analysis of patients undergoing cystectomy between 1995 and...

Refining the role of androgen deprivation therapy after radical prostatectomy

A rising prostate specific antigen (PSA) after radical prostatectomy represents a pivotal moment in prostate cancer management, with salvage radiation therapy (RT) the standard intervention. However, the optimal role and duration of androgen deprivation therapy (ADT) alongside RT remain debated....

Comparative effectiveness of nephron sparing surgery vs ablation

Nephron sparing surgery (NSS) and minimally invasive modality of thermal ablation have attracted great attention as an alternative surgical treatment to radical nephrectomy (RN) for renal tumours <4cm. High quality evidence comparing disease specific survival (DSS) is lacking. This issue...

Prostate cancer management 2 – metastatic disease

A 72-year-old gentleman is referred to you in the two-week wait clinic with a prostate specific antigen (PSA) of 22ug/L. He is otherwise fit and well and does not take any regular medication. His multi-parametric magnetic resonance imaging (mpMRI) shows...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...